SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
CART-ddBCMA, som for tiden undersøkes i en fase 2 pivotal studie, er Arcellx sin T-celleterapi som bruker selskapets nye syntetiske bindemiddel, D-Domain. Kite og Arcellx vil i fellesskap fremme og kommersialisere CART-ddBCMA-eiendelen i USA, og Kite vil kommersialisere produktet utenfor USA
BIL T-cellebehandling er blant banebrytende behandling for visse typer blodkreft. Det er mer enn 750 pågående kliniske studier in CAR T-Cell terapi i Kina akkurat nå. Pasienter som ønsker å melde seg på kan ta kontakt KreftFaks pasienttelefon på WhatsApp + 91 96 1588 1588 eller e-post til info@cancerfax.com.
Om Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory flere myelomer (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastisk syndrom, initiated in the fourth quarter of 2022.
Om Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Om Gilead Sciences
Gilead Sciences, Inc. er et biofarmasøytisk selskap som har forfulgt og oppnådd gjennombrudd innen medisin i mer enn tre tiår, med mål om å skape en sunnere verden for alle mennesker. Selskapet er forpliktet til å fremme innovative medisiner for å forebygge og behandle livstruende sykdommer, inkludert HIV, viral hepatitt og kreft. Gilead opererer i mer enn 35 land over hele verden, med hovedkontor i Foster City, California. Gilead Sciences kjøpte Kite i 2017.
